Register
Login:
Share:
Email Facebook Twitter


Exclusive: Hardman & Co call the lithium market: is a change in trend happening?
Tower Resources identify 18 million barrels of contingent reserves worth $118M in Cameroon




Share Price Information for Plethora Solutions Holdings PLC (PLE)


There is currently no data for Plethora Solutions Holdings PLC.




London South East Users info for Plethora Solutions Holdings PLC





View more Plethora Solutions Holdings PLC trades >>

Directors Deals for Plethora Solutions Holdings PLC (PLE)
Trade DateActionNotifierPriceCurrencyAmountHolding
28-Oct-15Notification of Holding
Trade Notifier Information for Plethora Solutions Holdings
James (Jim) Mellon held the position of Chairman at Plethora Solutions Holdings at the time of this trade.
 James (Jim) Mellon
00243758261
01-Apr-15Notification of Holding
Trade Notifier Information for Plethora Solutions Holdings
James (Jim) Mellon held the position of Chairman at Plethora Solutions Holdings at the time of this trade.
 James (Jim) Mellon
00246613861
29-Jan-15Notification of Holding
Trade Notifier Information for Plethora Solutions Holdings
James (Jim) Mellon held the position of Chairman at Plethora Solutions Holdings at the time of this trade.
 James (Jim) Mellon
00145974014
View more Plethora Solutions Holdings PLC directors dealings >>


The.Italian
Posts: 534
Premium Chat Member
Opinion:No Opinion
Price:0.00
RE: Life In The Old Boot Yet ?
Today 16:41
well i did post some time ago about the irony of being saved by the Boot!i suspect china hong kong and macau are probably going to prove of slightly greater significance but it is interesting to read that life still goes on.
on the uk front i understand the scepticism that it may be delayed but i am hopeful that it will materialise as stated by recordati and that it will provide a morale boost for the board and of greater significance an increased awareness profile and even in time a significant revenue contribution
Montezumarevenge
Posts: 14
Opinion:No Opinion
Price:0.00
Life In The Old Boot Yet ?
Today 15:31
Montezumarevenge
Posts: 14
Opinion:No Opinion
Price:0.00
RE: Recordati
Today 14:27
Far more likely in my view that the shift in strategy to focus on the UK has been driven by continued and increasing on line prescription sales over the last few months as traction is gained and is which is likely being driven by social media platforms and press articles.

This would also fit with a realisation that more pre launch preparation work and the raising of PE awareness is required for the smaller EU territories to ensure a worthwhile and adequately prepared launch.

The argument advanced by the ex CEO that a launch is worthwhile, however miniscule the revenues might be and however cheap the costs might be is even more curious. It is also incorrect on many grounds as is the comparison with other totally unrelated other classes of drugs.

The comparison should be with ineffective creams and anti-depressants that work on the central nervous system. Unfortunately the handful of NHS Trusts that have blacklisted Fortacin are too dumb to even recognise the ancillary costs of putting patients on anti- depressants and on a ling term basis.
Alquemie
Posts: 1,014
Opinion:No Opinion
Price:0.00
RE: Recordati
Fri 14:21
All very curious....

Fortacin has been listed in the Greek and Romanian national formularies for months, and, as in the other territories, with a urology sales force already in place, it could have been launched at very modest cost. Minuscule sales have never prevented the promotion of other portfolio products (Vitaros, Kentera, Urispas and other "for show" details).

And for a promotion sensitive product such as Fortacin, postponing launch in countries with a field force in place while perhaps launching in the the hardest market of all (no sales presence, no urology portfolio, NHS blacklisting, lowest per capita specialist representation), with the only viable option being remote prescribing and supply either directly or through a third-party), marks a strange shift in strategy.

Complete speculation on my part, but I'm aware that Recordati have recently received approval for a Urorec generic in the EU and while they have indicated an expectation of continued modest growth (largely in ex-core territories), I'm wondering whether they are looking to close out the urology franchise (at least in developed markets) early to focus on higher margin specialities.
bignose58
Posts: 2,028
Opinion:No Opinion
Price:0.00
RE: Recordati
Fri 12:52
Montezrevenge,

You are certainly right there, but then. Since a promise is a declaration of something to shareholders or a shareholder etc, then it can be considered as reneging. Anyway, the pont is they, like RP, are not following their statements of timed events.

Since the transfer of marketing etc to Recordati, RP has no longer any say in the matter. What is more interesting is whether RP is keeping tabs on what Recordati are doing. Surely there has to be some continued follow up. And although you are correct that RP don’t need to keep the market or shareholders updated, they did make the statement on follow up launches in h2 of 2018 which was made at the same time as the disappointing sales statement.

It seems to me that they are not following up and probably appreciate the news from outside that launches have been delayed from those stated. I Honestly thought after all these years things would now be different as the product is out there. Apparently not and shareholders are again left to wonder what’s going on. As stated, the UK launch may get even further delayed since credibility on launch dates is now questionable.

Anyway, I await any response from JG who I am sure will provide a perfectly good explanation..... ;-)
View more share chat for Plethora Solutions Holdings PLC (PLE) >>







Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.